Back to Search
Start Over
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
- Source :
- Breast cancer research : BCR, Vol. 13, no.1, p. R17 (2011)
- Publication Year :
- 2011
-
Abstract
- Anti-trastuzumab anti-Id scFv69, used as a therapeutic or prophylactic vaccine, protects mice from developing HER2-positive mammary tumors by inducing both anti-HER2 Ab1' antibody production and an anti-HER2 Th2-dependent immune response. These results suggest that scFv69 could be used as an anti-Id-based vaccine for adjuvant therapy of patients with HER2-positive tumors to reverse immunological tolerance to HER2.
Details
- Database :
- OAIster
- Journal :
- Breast cancer research : BCR, Vol. 13, no.1, p. R17 (2011)
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1104532968
- Document Type :
- Electronic Resource